May Highlights from Powerful Medical: PMcardio 3.0 Launch, STEMI Research, and Clinical Breakthroughs
May was a milestone month at Powerful Medical. From launching PMcardio for Individuals 3.0 and showcasing new explainable AI tools, to advancing STEMI detection through international research and clinical collaboration—discover the breakthroughs that are shaping the future of cardiac care.
May was a month of meaningful clinical progress and continued product innovation. From major study milestones to impactful conference presentations and pivotal product developments, here are some key highlights from the past few weeks.
Launching PMcardio for Individuals 3.0
We launched PMcardio 3.0, a major upgrade to our AI-powered ECG interpretation platform. Designed to support clinicians in acute care settings, this version delivers faster, explainable diagnostics for STEMI and STEMI-equivalents anytime, anywhere.
Key Improvements in PMcardio 3.0:
• Queen of Hearts™: Detects both typical and atypical occlusive MIs with high precision
• ECGxplain™: Visual heatmaps clarify the AI’s reasoning for each ECG interpretation
• Automated ECG digitization: Reads ECGs from photos, printouts, or screenshots in seconds
• Robust clinical performance: Independently confirmed in 19 international studies for early OMI detection
The update also enhances core features, including an extended monthly ECG analysis quota, diagnostic insights, full ECG history, and case complexity indicators to further streamline and support confident clinical decision-making.
Click here to try PMcardio 3.0 today.
New AI ECG Model Presented at EuroPCR
At this year’s EuroPCR, our Chief Medical Officer, Dr. Robert Herman, PhD, presented the feasibility of a new AI ECG model in development focusing on detecting the infarct-related artery (IRA).
The model demonstrated the ability to accurately predict the IRA even in cases that fall outside conventional STEMI criteria. Procedural and prognostic implications of this model will be evaluated in future studies.
All AI ECG TIMI Study Sites Now Active
The AI-ECG TIMI Study, a novel, international, multi-center study aimed at validating the use of AI to improve the detection and management of acute coronary syndromes (ACS), has reached a key operational milestone with all nine participating centers now fully active across Austria, Germany, and Switzerland. The final two Austrian centers, LKH Graz II – Standort West and LKH Hochsteiermark Standort-Bruck, recently received ethics approval, enabling full-scale patient enrollment across the entire network and progressing toward a goal of over 700 enrolled patients.
The next phase will focus on harmonizing data across the international centers and generating real-world evidence to validate AI-powered ECG interpretation in the diagnosis of acute coronary syndromes.
For a full study overview and more details, click here.
Queen of Hearts™ Recognized at DGK Early Career Investigator Competition
At this year’s DGK Congress, Dr. Sascha Macherey-Meyer from University Hospital Cologne earned an impressive second place in the DGK Early Career Investigator Competition for his presentation on new findings from the evaluation of the latest Queen of Hearts™ PMcardio AI ECG model. His submission builds on last year’s study evaluating our original Queen of Hearts™ model, further validating the impact of AI in detecting acute coronary syndromes.
During the congress, we also partnered with prof. Dr. Benjamin Meder and Dr. Ali Amr from the University Hospital Heidelberg for a live ECG quiz, “Test the Cardiologists Against AI”, comparing expert interpretation with real-time results from PMcardio—bringing clinical engagement and innovation to the spotlight.
With every study and product milestone, we move one step closer to better outcomes in acute cardiac care.
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
